UnitedHealth Tops Quarterly Estimates, Raises 2026 Profit Outlook as Insurer Gains Ground on Medical Costs
Why It Matters
UnitedHealth Group, the nation’s largest private health insurer, delivered stronger-than-expected first-quarter results and raised its full-year profit outlook, signaling that the company is gaining control over elevated medical costs that have pressured the broader insurance industry for more than two years.
The earnings report carries significant weight for American consumers, employers, and Medicare beneficiaries who rely on UnitedHealth’s coverage — and for the Trump administration’s ambitious plans to expand Medicare coverage of obesity drugs.
What Happened
UnitedHealth reported first-quarter results on Tuesday that beat Wall Street estimates across key metrics, driven by improved cost management and operational streamlining under a new leadership team.
The company posted net income of $6.28 billion, or $6.90 per share, on revenue of $111.72 billion — up from $109.58 billion in the same quarter a year ago. Excluding items such as business divestitures and restructuring charges, the company earned $7.23 per share.
Both UnitedHealthcare, the company’s insurance arm, and Optum, its health services unit, topped analysts’ sales estimates for the quarter. The results came just weeks after the Trump administration finalized a larger-than-expected 2027 payment rate increase for Medicare Advantage plans, providing a significant boost to insurer stocks.
By the Numbers
Key figures from UnitedHealth’s first-quarter report:
• $111.72 billion — Total revenue for Q1 2026, up from $109.58 billion in Q1 2025
• $18.25 per share — Raised 2026 adjusted earnings outlook, up from a prior forecast of more than $17.75 per share
• $439 billion — Full-year revenue guidance, maintained from earlier projections
• 83.9% — Medical benefit ratio for Q1, an improvement from 84.8% a year ago and better than the 85.5% analysts had projected
• $6.28 billion — Net income for the quarter, essentially flat compared with $6.29 billion in the prior-year period
Managing Medical Costs — A Two-Year Struggle
A critical measure of insurer profitability — the medical benefit ratio — improved to 83.9% in the first quarter. A lower ratio indicates the company collected more in premiums than it paid out in medical claims, boosting margins.
Analysts had expected the ratio to come in at 85.5%, making UnitedHealth’s result a notable outperformance. The company attributed the improvement to strong cost management and the release of previously set-aside reserves for unprofitable Optum contracts.
However, UnitedHealth acknowledged that “consistently elevated” medical costs partially offset those gains. Insurers across the industry have faced pressure from patients seeking care they delayed during the pandemic, as well as surging demand for high-cost specialty drugs, including GLP-1 obesity treatments from manufacturers like Eli Lilly and Novo Nordisk.
“We are continuing to help simplify and modernize health care for the people and care providers we serve, bringing greater value, affordability, transparency and connectivity,” said CEO Stephen Hemsley in the company’s earnings release.
Medicare Obesity Drug Coverage Hangs in the Balance
Beyond the earnings beat, investor and policy attention is focused on whether UnitedHealth will participate in the Trump administration’s program to cover GLP-1 obesity drugs under Medicare starting next year.
As the largest provider of privately run Medicare Advantage plans, UnitedHealth’s participation is widely seen as essential for the program to move forward meaningfully. The company faced a Monday deadline to notify the federal government of its intent.
Bobby Hunter, head of UnitedHealth’s government programs, offered a cautious response on the company’s earnings call. “We’d like to find a path, yes, there on coverage over time, but there are some notable challenges and outstanding questions with the currently planned structure,” Hunter said. “So, we’re still working through that process internally and we look forward to continuing the dialogue with CMS.”
Zoom Out
UnitedHealth’s turnaround strategy includes shrinking its membership base, divesting the U.K. business of its Optum unit, heavily investing in artificial intelligence, and increasing transparency — measures the company says are designed to restore both profitability and public trust after a difficult two-year stretch.
The broader health insurance sector has faced similar headwinds, with Medicare Advantage plans in particular absorbing higher-than-expected medical costs. The Trump administration’s decision to finalize a larger Medicare Advantage payment rate increase for 2027 provided a meaningful financial tailwind for UnitedHealth and its competitors.
What’s Next
UnitedHealth’s ongoing dialogue with the Centers for Medicare and Medicaid Services over GLP-1 drug coverage will be closely watched in coming weeks. The company’s decision could shape the scope of the administration’s obesity drug initiative for millions of Medicare beneficiaries.
Investors will also monitor how UnitedHealth executes its operational restructuring, including the planned Optum UK divestiture and its broader push to integrate artificial intelligence into its care management operations through the remainder of 2026.